06 Jun, 14:19 - Indian

SENSEX 82178.03 (0.90)

Nifty 50 24990 (0.97)

Nifty Bank 56636.7 (1.57)

Nifty IT 37180.65 (0.20)

Nifty Midcap 100 59051.9 (1.28)

Nifty Next 50 67954 (1.20)

Nifty Pharma 21674.9 (0.14)

Nifty Smallcap 100 18604 (0.93)

06 Jun, 14:19 - Global

NIKKEI 225 37741.61 (0.50)

HANG SENG 23792.55 (-0.48)

S&P 5980.75 (0.38)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(03 Jun 2025, 13:07)

Medicamen Biotech rallies after securing USFDA approval for Bortezomib injection

Medicamen Biotech soared 5.39% to Rs 440 after the company has received its first Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA) for Bortezomib for injection 3.5 mg.


The ANDA pertains to Bortezomib for Injection, 3.5 mg single-dose vial. The USFDA has determined that the product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Velcade for Injection, 3.5 mg/vial, marketed by Takeda Pharmaceuticals U.S.A. Inc. (NDA-021602).

This milestone marks a significant step forward in the company’s strategy to enter regulated markets. The Bortezomib API was developed in-house through the company’s R&D efforts and manufactured at Shivalik Rasayan, which holds USDMF 036171.

The achievement underscores Medicamen’s capabilities in successfully developing and commercializing products using its own R&D and API manufacturing infrastructure, built over the past few years. It also highlights the company’s strong commitment to stringent quality standards, robust regulatory compliance, and adherence to Current Good Manufacturing Practices (cGMP).

Medicamen reaffirmed its dedication to maintaining the integrity of its products and systems as it continues to expand its footprint in the U.S. market.

Medicamen Biotech is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations.

The company’s consolidated net profit rose 13.6% to Rs 2.42 crore in Q4 FY25, despite a 37.4% decline in revenue from operations to Rs 29.61 crore compared to the year-ago period.

More News
More Company News View Company Information

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +